Dr. Michael Iskander, MD

Dr. Iskander practices at Cedars-Sinai Medical Center in Los Angeles, California, part of Cedars-Sinai Health System.

Dr. Iskander's NPI, 1104352608, was assigned on May 4, 2017. Dr. Iskander holds California license A164857.

Dr. Iskander's primary practice is Cedars-Sinai Medical Center, at 8700 Beverly Blvd, Los Angeles, CA 90048 in Los Angeles County. The practice phone is (310) 423-5000.

Dr. Iskander's primary practice is Cedars-Sinai Medical Center in Los Angeles, California, part of Cedars-Sinai Health System. Dr. Iskander is also affiliated with Cedars-Sinai Marina Hospital. The medical group on file is Inpatient Specialist of California PC. Dmand AI also links Dr. Iskander to 1 more hospital, 3 medical groups, 2 home health agencies and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Iskander practices, 6 sites in all. Vendor and product names are available with a free account.

Internal medicine is Dr. Iskander's primary specialty in the NPI Registry, under taxonomy code 207R00000X. Dr. Iskander is licensed in California.

CMS data shows 1,846 Medicare services from Dr. Iskander across 7 procedure codes in 2024, for 402 Medicare patients. Medicare paid $175,750 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 402 Medicare patients who saw Dr. Iskander in 2024. The largest group is 65 to 74, with 137 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 58% are also on Medicaid. Their average risk score is 3.47, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Iskander's median patient age at 72, with 54% women.

In 2024, Dr. Iskander wrote 377 Medicare Part D claims for 138 patients. 87% of them were for generic drugs. CMS names the drug for 75 of them, across 5 drugs with 11 or more claims each, at $8,939 in total drug cost. In 2023, CMS named 46 claims across 3 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 75 out of 100 for Dr. Iskander for performance year 2024, reported individually. Dr. Iskander accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

CMS Open Payments shows 3 general payments to Dr. Iskander from 2 drug and device companies from 2019 to 2021. Food and beverage make up the largest share, 100% of the total. Amgen Inc. paid the most, $138.